Champions OncologyCSBR +7.98%64 Current Ratio is 0.98 as of Jan. 2026, which is 2% above its 10-year median of 0.96. GuruFocus rates CSBR with a GF Score™ of 64/100 and a GF Value™ of $6.62 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,416 Biotechnology companies, Champions Oncology ranks worse than 84.68% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Champions Oncology's current ratio for the quarter that ended in Jan. 2026 was 0.98.
Champions Oncology has a current ratio of 0.98. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Champions Oncology has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Champions Oncology's Current Ratio or its related term are showing as below:
CSBR'
s Current Ratio Range Over the Past 10 Years
Min: 0.57 Med: 0.96 Max: 1.46
Current: 0.98
During the past 13 years, Champions Oncology's highest Current Ratio was 1.46. The lowest was 0.57. And the median was 0.96.
CSBR's Current Ratio is ranked worse than 84.68% of 1416
companies
in the Biotechnology industry
Industry Median: 3.885
vs CSBR: 0.98
Champions Oncology (NAS:CSBR) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Champions Oncology Current Ratio Related Terms
Champions Oncology Current Ratio Historical Data
* Premium members only.
The historical data trend for Champions Oncology's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSBR vs ANVS, HYFT, GANX: Current Ratio Comparison
For the Biotechnology subindustry, Champions Oncology's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Champions Oncology Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Champions Oncology's Current Ratio distribution charts can be found below:
* The bar in red indicates where Champions Oncology's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Champions Oncology (CSBR) has a Current Ratio of 0.98 as of Jan. 2026. This is near median its historical median of 0.96. Over the past decade, Champions Oncology's Current Ratio has ranged from 0.57 to 1.46. According to the industry distribution chart, Champions Oncology ranks #1199 out of 1416 companies in the Biotechnology industry, placing it in the top 84.7%.
Is Champions Oncology's Current Ratio too high?
Champions Oncology's current Current Ratio of 0.98 is near median its 10-year median of 0.96. Over the past 10 years, this metric has ranged from a low of 0.57 to a high of 1.46. The Biotechnology industry median Current Ratio is 3.89. Champions Oncology's value of 0.98 is 74.8% below this industry median. Based on the distribution chart, Champions Oncology ranks #1199 out of 1416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Champions Oncology has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Champions Oncology's Current Ratio compare to ANVS and HYFT?
According to the Biotechnology industry distribution chart, Champions Oncology ranks #1199 out of 1416 companies for Current Ratio. This places Champions Oncology in the lower half of its industry. The industry median Current Ratio is 3.89. Champions Oncology's value of 0.98 is 74.8% below this benchmark. Historically, Champions Oncology's own Current Ratio has ranged from 0.57 to 1.46 over the past decade. While the company's 10-year median is 0.96 vs. the industry median of 3.89, Champions Oncology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Champions Oncology's current Current Ratio of 0.98 is 74.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Champions Oncology's current Current Ratio is 0.98, which is near median its own 10-year median of 0.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Champions Oncology stock overvalued right now?
Based on GuruFocus' analysis, Champions Oncology (CSBR) is currently considered Fairly Valued. The stock's GF Value™ is $6.62, compared to a current price of $6.63 — trading 0.2% above its estimated fair value. The current Current Ratio is 0.98, which is near median its 10-year median of 0.96 and 74.8% below the Biotechnology industry median of 3.89. Champions Oncology's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Champions Oncology (CSBR), the current Current Ratio is 0.98 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Champions Oncology (CSBR) Overvalued in 2026?
Based on GuruFocus' analysis, Champions Oncology stock appears to be overvalued.
The current stock price of $6.63 is trading 0.2% above its estimated GF Value™ of $6.62.
GuruFocus considers Champions Oncology to be Fairly Valued.
Key valuation signals for CSBR:
Current Ratio: 0.98 (near median its 10-year median of 0.96)
GF Value™: $6.62 vs. price of $6.63 (0.2% above fair value)
Industry Position: 74.8% below the Biotechnology median (#1199 of 1416)
No single metric tells the full story. See the CSBR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
64GF Score
Get the complete analysis for CSBR
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBR has been successfully added to your 
